Search Results

You are looking at 21 - 30 of 68 items for :

  • "temsirolimus" x
  • Refine by Access: All x
Clear All
Full access

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Randomized, Phase II Trial of AZD6244 Alone and AZD6244 Plus Temsirolimus for Soft-Tissue Sarcomas

Full access

Evaluating Combination Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer Principal Investigator: Eric Sherman, MD Condition: Thyroid cancer Institution: Memorial Sloan-Kettering Cancer Center A phase II

Full access

scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck

Full access

Eric Jonasch

evidence). Bevacizumab plus interferon is also a category 1 recommendation for these risk groups. Temsirolimus remains an option for patients at poor risk (category 1), but Dr. Jonasch said its use is declining. Temsirolimus is a category 2B

Full access

Robert W. Carlson and Eric Jonasch

cabozantinib. The mTOR inhibitors include temsirolimus and everolimus, and immunomodulatory agents include the older drug interleukin-2 (IL-2) and now nivolumab. A number of questions remain regarding the use of these drugs, including the best frontline

Full access

Elizabeth R. Plimack and Gary R. Hudes

endothelial growth factor (VEGF)-directed therapies (sorafenib, sunitinib, pazopanib, and bevacizumab) and mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus). With such a large number of treatment options, selecting among them for a

Full access

Eric Jonasch

Kidney Cancer, first-line options with randomized phase II evidence of benefit include the FDA-approved agents sunitinib, pazopanib, and the combination of bevacizumab and interferon. Furthermore, temsirolimus is indicated for patients with a poor

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar

multiple converging cell signaling pathways regulating micronutrients, cell growth, apoptosis, and angiogenesis. 4 - 6 Two mTOR inhibitors, temsirolimus and everolimus, are FDA-approved for the treatment of patients with advanced RCC, although everolimus

Full access

was changed from a category 2A to a category 3 recommendation. ∘ Temsirolimus was changed from a category 2A to a category 3 recommendation. ➤ Subsequent Therapy for Clear Cell Histology: ⋄ Preferred Regimens: ∘ Ipilimumab + nivolumab was

Full access

Frank Xiaoqing Liu, Kirstin Heinrich, Catarina Neves, Ying Zheng, and Adam Kasle

, temsirolimus, and pembrolizumab+axitinib (Pem+Ax). Cost elements of the model included drug acquisition, administration, adverse event management, monitoring, and subsequent treatment. Model inputs were mostly obtained from published literature, prescribing